<DOC>
	<DOCNO>NCT00638313</DOCNO>
	<brief_summary>PF 04603629 long act exendin propose treatment Type 2 diabetes mellitus . The purpose study characterize safety , tolerability , pharmacokinetics glucose lower capability follow single subcutaneous dose .</brief_summary>
	<brief_title>Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Type 2 diabetes mellitus Hb A1c low equal 11 % Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) . Evidence diabetic complication significant endorgan damage</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>GLP-1</keyword>
</DOC>